


Crisnatol

Cat. No.:	HY-108999A
CAS No.:	96389-68-3
Molecular Formula:	C ₂₃ H ₂₃ NO ₂
Molecular Weight:	345.43
Target:	DNA/RNA Synthesis
Pathway:	Cell Cycle/DNA Damage
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (289.49 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.8949 mL	14.4747 mL	28.9494 mL
	5 mM	0.5790 mL	2.8949 mL	5.7899 mL
	10 mM	0.2895 mL	1.4475 mL	2.8949 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Crisnatol (BWA770U) is an orally active and anticancer agent, and a member of the arylmethylaminopropanediol class of DNA intercalators. Crisnatol shows in vitro cytotoxicity against human breast cancer cells, but not normal human skin fibroblasts^{[1][2][3]}.

In Vitro

Crisnatol (1.3 µg/mL; 24-72 h) inhibits the replication of HepG2 cells, decreases cell viability by 35%^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay^[2]

Cell Line:	HepG2 cells
Concentration:	1.3 µg/mL
Incubation Time:	24 hours, 48 hours, 72 hours, and 126 hours
Result:	Inhibited cell viability at 48 hr.

In Vivo

Crisnatol (25 mg/kg; p.o.; single dose) shows oral activity and shows stable metabolite profile extract of rat feces by autoradiography^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Adams DJ. In vitro pharmacodynamic assay for cancer drug development: application to crisanol, a new DNA intercalator. *Cancer Res.* 1989 Dec 1;49(23):6615-20.
- [2]. Patel DK, et al. Metabolism of a novel antitumor agent, crisanol, by a human hepatoma cell line, Hep G2, and hepatic microsomes. Characterization of metabolites. *Biochem Pharmacol.* 1991 Jul 5;42(2):337-46.
- [3]. Patel DK, et al. Disposition, metabolism, and excretion of the anticancer agent crisanol in the rat. *Drug Metab Dispos.* 1991 Mar-Apr;19(2):491-7.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA